A new suite for HPAPI conjugate production was added to St. Louis plant and a new reactor was installed at Arklow site.

SAFC Pharma of the Sigma-Aldrich group reports that it has a new suite at its St. Louis, MO, facility that will produce high-potency API (HPAPI) conjugates for cancer drug development and a new reactor at its Arklow, Ireland, site that will expand large-scale manufacturing by approximately 15%.

The 600 sq. ft. suite at the St. Louis campus will enable the conjugation of HPAPIs to a variety of targeted delivery molecules including mAbs, the company explains. It can also accommodate early-stage clinical supplies and multikilogram quantities, with the capability to expand production up to commercial-scale.

In Arklow, the $4 million project involved the installation and start-up of a 6,000 L Hastalloy® reactor for large-scale API production, increasing the total capacity at the site to 96,000-liter, with a reactor range from 250 to 8,000 liters. Both large- and small-scale manufacturing is possible. The 209,000-cubic-feet Arklow complex is cGMP, FDA, and IMB inspected as well as fully validated, the company notes.

Previous articleScientists Create Method to Control Protein Degradation
Next articleBayer to Build On Kentucky Bioproccessing’s Facility for Plant-Made Biopharmaceutical Production